One of largest API production facilities to be built in Russia

26 October 2020

One of Russia’s largest plants for the production of active pharmaceutical ingredients (APIs) will soon be built in the St Petersburg region by the local enterprise Active Component JSC, a leading producer of pharmaceutical ingredients and drugs in the country, reports The Pharma Letter’s local correspondent.

According to some Russian media reports, the project will be implemented on the basis of a special investment contract, which has been recently signed between the partners.

Under its terms, the plant will specialize on the production of a wide range of active ingredients and have the status of one of the largest in the country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK